More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$11.39B
EPS
-2.18
P/E ratio
--
Price to sales
17.48
Dividend yield
--
Beta
1.284523
Previous close
$82.85
Today's open
$82.98
Day's range
$79.93 - $83.27
52 week range
$28.12 - $95.49
show more
CEO
Christopher Anzalone
Employees
609
Headquarters
Pasadena, CA
Exchange
Nasdaq Global Select
Shares outstanding
141254467
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • 12 hours ago

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC.
Business Wire • 19 hours ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Seeking Alpha • Sep 10, 2026

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
The transaction was valued at $1 million. The sale reduced the director's direct equity holdings by 9%.
The Motley Fool • Sep 6, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor Global Healthcare Conference – September 9-11, 2026 Type: Fireside Chat Presentation Date/Time: September 10, 2026, 10:55 am EDT Morgan Stanley 24th Annual Global Healthcare Conference – September 14-16, 2026 Type: Fireside Chat Presentation Date/Time: September 15, 2026, 11:30 am EDT H.C. Wainwright 28th Ann.
Business Wire • Sep 3, 2026

Arrowhead's Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials
Arrowhead Pharmaceuticals NASDAQ: ARWR presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial reductions in triglycerides and acute pancreatitis events versus placebo. The company said the data were presented at the European Society of Cardiology Congress in Munich and have been accepted for publication in a major medical journal.
MarketBeat • Aug 31, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript
Seeking Alpha • Aug 31, 2026

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)-- #arrowheadpharma--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a Hot Line Late-Breaking Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. SHASTA-3 and SHASTA-4 met their primary and all prespecified secondary endpoints and demonstrated deep and durable reductions in triglycerides (TG),.
Business Wire • Aug 30, 2026

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich, Germany. ESC 2026 Presentation Details Date & Time: Sunday, August 30, 2026, 17:30 CEST Session Title: HOT LINE 9 Late-breaking Science Session Location: Munich Auditorium-Hall B3 Title: Plozasiran in patients with severe hypertriglyceridemia: the SHASTA-3 and SHASTA-4 pivotal trial 12-month.
Business Wire • Aug 24, 2026

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that people in Germany who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) are the among first in the European Union to have a new treatment option to reduce dangerously high levels of triglycerides (TGs, a type of fat) in their bloodstream. Following its marketing authorization by the European Commission in June 2026, REDEMPLO® (plozasiran) is now listed in the.
Business Wire • Aug 17, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Arrowhead Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.